Prevention and treatment of thromboembolic disorders

Details for Australian Patent Application No. 2006208613 (hide)

Owner Bayer Schering Pharma Aktiengesellschaft

Inventors Park, Son-Mi; Kubitza, Dagmar; Misselwitz, Frank; Wehling, Klaus

Agent Davies Collison Cave

Pub. Number AU-B-2006208613

PCT Pub. Number WO2006/079474

Priority 05001893.6 31.01.05 EP

Filing date 19 January 2006

Wipo publication date 3 August 2006

Acceptance publication date 16 June 2011

International Classifications

A61K 31/00 (2006.01)

A61K 31/5377 (2006.01)

A61P 7/02 (2006.01) Drugs for disorders of the blood or the extracellular fluid

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

Event Publications

23 August 2007 PCT application entered the National Phase

  PCT publication WO2006/079474 Priority application(s): WO2006/079474

14 May 2009 Assignment before Grant

  Bayer HealthCare AG The application has been assigned to Bayer Schering Pharma Aktiengesellschaft

16 June 2011 Application Accepted

  Published as AU-B-2006208613

8 September 2011 Alteration of Name

  The name of the applicant has been altered to Bayer Pharma Aktiengesellschaft

13 October 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006208618-The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome

2006208606-An injection device with an end of dose feedback mechanism